115 related articles for article (PubMed ID: 17215077)
21. C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer.
Motoyama S; Miura M; Hinai Y; Maruyama K; Usami S; Nakatsu T; Saito H; Minamiya Y; Suzuki T; Ogawa J
J Am Coll Surg; 2009 Oct; 209(4):477-83. PubMed ID: 19801321
[TBL] [Abstract][Full Text] [Related]
22. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
23. The evaluation of effects of demographic features, biochemical parameters, and cytokines on clinical outcomes in patients with acute renal failure.
Kadiroglu AK; Sit D; Atay AE; Kayabasi H; Altintas A; Yilmaz ME
Ren Fail; 2007; 29(4):503-8. PubMed ID: 17497476
[TBL] [Abstract][Full Text] [Related]
24. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
25. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
26. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
27. A review of the BIG results: the Breast International Group 1-98 trial analyses.
Doughty JC
Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
[TBL] [Abstract][Full Text] [Related]
28. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
29. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
[TBL] [Abstract][Full Text] [Related]
30. The effect of massage on cellular immunity, endocrine and psychological factors in women with breast cancer -- a randomized controlled clinical trial.
Billhult A; Lindholm C; Gunnarsson R; Stener-Victorin E
Auton Neurosci; 2008 Jun; 140(1-2):88-95. PubMed ID: 18474451
[TBL] [Abstract][Full Text] [Related]
31. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.
Nicolini A; Carpi A; Ferrari P; Rossi G
Cancer Lett; 2008 May; 263(1):122-9. PubMed ID: 18241981
[TBL] [Abstract][Full Text] [Related]
33. Pattern of tumor recurrence in initially nonmetastatic breast cancer patients: distribution and frequency of metastases at unusual sites.
Sanuki-Fujimoto N; Takeda A; Amemiya A; Ofuchi T; Ono M; Yamagami R; Hatayama J; Kunieda E; Shigematsu N
Cancer; 2008 Aug; 113(4):677-82. PubMed ID: 18613072
[TBL] [Abstract][Full Text] [Related]
34. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
36. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
37. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
38. CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer.
Motoyama S; Miura M; Hinai Y; Maruyama K; Usami S; Saito H; Minamiya Y; Satoh S; Murata K; Suzuki T; Ogawa J
Ann Surg Oncol; 2009 Sep; 16(9):2479-85. PubMed ID: 19495883
[TBL] [Abstract][Full Text] [Related]
39. Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome.
Nassar A; Cohen C; Cotsonis G; Carlson G
Breast J; 2008; 14(2):147-52. PubMed ID: 18248563
[TBL] [Abstract][Full Text] [Related]
40. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
